Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND ORPHAN DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

career opportunities

We are growing and need great talent. We currently have lots of exciting opportunities, including the following positions:

Click here to apply

spotlight

July 16, 2014

bluebird bio Appoints Mark Vachon to its Board of Directors

Read More

July 7, 2014

bluebird bio Announces Proposed Public Offering of Common Stock

Read More

June 30, 2014

bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company

Read More

June 14, 2014

bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate

Read More